Advertisement

Gutartige Brusterkrankungen

  • H. Junkermann

Zusammenfassung

Die klinische Diagnose „Mastopathie“ umfaßt gutartige, mehr oder weniger diffuse Veränderungen der weiblichen Brustdrüse (Verdichtung, Knoten) und damit einhergehende Beschwerden (Mastodynie). Pathologisch-anatomisch findet sich bei klinischer Mastopathie ein buntes Bild histologischer Veränderungen. Neue pathologisch-anatomische Einteilungen differenzieren in erster Linie nach dem Entartungsrisiko.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. D’Agata R, Aliffi A, Maugeri G, Mongioi A, Vicari E, Gulizia S (1982) Dynamics of Prl release in galactorrhoeic normoprolactinaemic women. Acta Endocrinol 101: 1–4PubMedGoogle Scholar
  2. Ahumada JC, del Castillo EB (1932) Amenorrhea y galactorrhea. Bol Soc Obstet Ginec of Buenos Aires 11: 64–67Google Scholar
  3. Aksu MF, Tzingounis VA, Greenblatt RB (1978) Treatment of benign breast disease with danazol: a follow-up report. J Reprod Med 21: 181–184PubMedGoogle Scholar
  4. Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Nielsen J (1977) Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial. Br J Obstet Gynaecol 84: 370–374Google Scholar
  5. Arabin B, v. Fournier D, Kubli F, Müller A, Weber E (1985) Probleme und Grenzen der mammographischen Karzinomdiagnostik: Vergleich der präoperativen radiologischen Diagnose mit dem histologischen Befund bei 335 Patientinnen mit subkutaner Mastektomie. Geburtshilfe Frauenheilkd 45: 595–603PubMedCrossRefGoogle Scholar
  6. Argonz J, del Castillo EB (1953) A syndrome characterized by estrogenic insufficiency, galactorrhea, and decreased urinary gonadotropin. J Clin Endocrinol 13: 79CrossRefGoogle Scholar
  7. Ariel IM (1973) Enovid therapy (norethynodrel with mestranol) for fibrocystic disease. Am J Obstet Gynecol 117: 453–459PubMedGoogle Scholar
  8. Asch RH (1977) The use of an impeded androgen–danazol–in the management of benign breast disorders. Am J Obstet Gynecol 127: 130–134PubMedGoogle Scholar
  9. Ashikari R, Huvos GH, Snyder RE, Lucas JC, Hutter RVP, McDivitt RW, Schottenfeld D (1974) A clinicopathologic study of atypical lesions of the breast. Cancer 33: 310–317PubMedCrossRefGoogle Scholar
  10. Atkins HJB (1949) The effect of endocrines on fibroadenosis. Br Med J: 750–752Google Scholar
  11. Ayers JWT, Gidwani GP (1983) The „luteal breast“: hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertil Steril 40: 779–784PubMedGoogle Scholar
  12. Azzopardi JG (1979) Problems in breast pathology. Saunders, LondonGoogle Scholar
  13. Bässler R, Schulze G, Schriever D (1970) Histochemische Untersuchungen am Bindegewebe der hormonal stimulierten Mamma. Beitr pathol Anat 140: 212–236PubMedGoogle Scholar
  14. Bässler R (1978) Pathologie der Brustdrüse. In: Dörr W, Seifert G, Uehlinger E (Hrsg) Spezielle pathologische Anatomie, Bd 11. Springer, Berlin Heidelberg New YorkGoogle Scholar
  15. Bauer M, v. Fournier D, Späh U, Kubli F, Jansa J (1982) Behandlungsergebnisse bei der Mastopathie. In: Frischbier HJ (Hrsg) Die Erkrankungen der weiblichen Brustdrüse. Thieme, StuttgartGoogle Scholar
  16. Berta L, Frairia R, Bumma C, Navello C, Mossetti C, Rovero E, Gaidano G (1983) Hormonal pattern and sex hormone binding globulin in plasma of women with cystic breast disease. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven, New York, pp 123–126Google Scholar
  17. Bischoff J, Rebhan EM, Prestele H, Becker H (1980) Serum-Prolaktin und Anamnesevergleich bei Mammazysten und zystischer Mastopathie. Geburtshilfe Frauenheilkd 40: 65–71PubMedCrossRefGoogle Scholar
  18. Bischoff J, Mulz D, Knüpfer A, Becker H (1981) Therapie von Mammazysten mit 2-alpha-Bromergokriptin. Geburtshilfe Frauenheilkd 41: 635–637PubMedCrossRefGoogle Scholar
  19. Blichert-Toft M, Nyboe Andersen A, Henriksen OB, Mygind T (1979) Treatment of mastalgia with bromocriptine: a double-blind cross-over study. Br Med J: 237Google Scholar
  20. De Boever J, Verheugen C, van Maele G, Vandekerckhove D (1983) Steroid concentrations in serum glandular breast tissue, and breast cyst fluid of control and progesterone-treated patients. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven, New York, pp 93–99Google Scholar
  21. Bohnet HG (1981) Prolaktin and seine Bedeutung für die Frau. In: Schirren C, Semm K (Hrsg) Fortschritte der Fertilitätsforschung 9. Grosse, BerlinGoogle Scholar
  22. Bohnet HG, Gómez F, Friesen HG (1977) Prolactin and estrogen binding sites in the mammary gland of the lactating and non-lactating rat. Endocrinology 101: 1111–1121PubMedCrossRefGoogle Scholar
  23. Brennan MJ, Bulbrook RD, Deshpande N, Wang DY (1973) Urinary and plasma androgens in benign breast disease. Lancet I: 1076–1079Google Scholar
  24. Bruning PF, Bonfrèr JMG, Bobrow L, de Jong-Bakker M, Hart AAM, Misdorp W (1984) Plasma hormones in premenopausal women with benign breast disease. In: International Congress, endocrinology of the breast, Torino, Italy. NY Acad Sci (Abstract 102 )Google Scholar
  25. Carlström K, Döberl A, Gershagen S, Rannevik G (1984) Peripheral levels of androgens and of some steroid sensitive plasma proteins in patients with fibrocystic breast disease. In: International Congress, endocrinology of the breast, Torino, Italy. NY Acad Sci (Abstract 103 )Google Scholar
  26. Chiari J (1852) Anomalien der Größe. In: Klinik der Geburtshilfe and Gynäkologie. Enke, ErlangenGoogle Scholar
  27. Cole EN, Sellwood RA, England PC, Griffiths K (1977) Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. Eur J Cancer 13: 597–603PubMedGoogle Scholar
  28. Colin C, Gaspard U, Lambotte R (1978) Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol. Arch Gynäkol 225: 7–13PubMedCrossRefGoogle Scholar
  29. Davajan V, Kletzky 0, March ChM, Roy S, Mishell DR Jr (1978) The significance of galactorrhea in patients with normal menses, oligomenorrhea, and secondary amenorrhea. Am J Obstet Gynecol 130: 894–904PubMedGoogle Scholar
  30. Dhont M, Delbeke L, VanEyck J, Voorhoof L (1979) Danazol treatment of chronic cystic mastopathy; a clinical and hormonal evaluation. Postgrad Med J 55: 66–70PubMedGoogle Scholar
  31. Durning P, Sellwood RA (1982) Bromocriptine in severe cyclical breast pain. Br J Surg 69: 248–249PubMedCrossRefGoogle Scholar
  32. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312: 146–151PubMedCrossRefGoogle Scholar
  33. England PC, Skinner LG, Cottrell KM, Sellwood RA (1974) Serum oestradiol-17ß in women with benign and malignant breast disease. Br J Cancer 30: 571–576PubMedCrossRefGoogle Scholar
  34. Ernster VL (1981) The epidemiology of benign breast disease. Epidemiol Rev 3: 184–202PubMedGoogle Scholar
  35. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL (1986) Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet I: 287–288Google Scholar
  36. Ferenczy A (1979) Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 133: 859–867PubMedGoogle Scholar
  37. Ferguson DJP, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the „resting“ human breast. Br J Cancer 44: 177–181PubMedCrossRefGoogle Scholar
  38. Forbes AP, Hennemann PH, Griswold GC, Albright F (1954) Syndrome characterized by galactorrhea, and low urinary FSH: Comparison with acromegaly and normal lactation. J Clin Endocrinol 14: 265Google Scholar
  39. von Fournier D, Kubli F, Junkermann H, Bauer M, Legler U, Arabin B, Müller A (1984) Medikamentöse and operative Therapie der Mastopathie in Abhängigkeit vom Entartungsrisiko. Frauenarzt 4: 27–39Google Scholar
  40. Frantz VK, Pickren JW, Melcher GW, Auchincloss H jr (1951) Incidence of chronic cystic disease in so-called „normal breasts“. A study based on 225 postmortem examinations. Cancer 4: 762–783PubMedCrossRefGoogle Scholar
  41. Frommel R (1882) Über puerperale Atrophie des Uterus. Z Geburtshilfe Gynakol 7: 305–318Google Scholar
  42. Gangemi M, Velasco M, Graziottin A, Licori D, Marchesoni D (1981) Bromoergocriptin therapy in eumenorrhoic patients presenting galactorrhea. Clin Exp Obstet Gynacol 2: 79–82Google Scholar
  43. Geschickter ChF (1948) Diseases of the breast; diagnosis, pathology, treatment, 2nd edn. Lippincott, PhiladelphiaGoogle Scholar
  44. Geschickter ChF, Hartman CG (1959) Mammary response to prolonged estrogenic stimulation in the monkey. Cancer 12: 767–781PubMedCrossRefGoogle Scholar
  45. Göbel R (1984) Results of the clinical evaluation of danazol in benign breast disease compared with local treatment, gestagens and bromocriptine. In: Baum M, George WD, Hughes LE (eds) Benign breast disease. The Royal Society of Medicine, London 76: 115–120Google Scholar
  46. Gorins A, Cordray JP (1984) Hormonal profile of benign breast disease and premenstrual mastodynia. Eur J Gynaecol Oncol 1: 1–10Google Scholar
  47. Grattarola R (1978) Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast. Cancer Res 38: 3051–3054Google Scholar
  48. Graziottin A, Sopracordevole F, Velasco M, Grella PV (1984) Plasma prolactin in women with mastodynia. Clin Exp Obstet Gynecol 3: 113–115Google Scholar
  49. Greenblatt B, Ben-Nun I (1980) Danazol in the treat- ment of mammary dysplasia. Drugs 19: 349–355PubMedCrossRefGoogle Scholar
  50. Haagensen CD (1971) Diseases of the breast, 2nd edn. Saunders, PhiladelphiaGoogle Scholar
  51. Haagensen CD, Bodian C, Haagensen DE jr (1981) Breast carcinoma: risk and detection. Saunders, PhiladelphiaGoogle Scholar
  52. Hammond GL, Nisker JA, Jones LA, Siiteri PK (1980) Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem 11: 5023–5026Google Scholar
  53. Jones JR, Gentile GP (1975) Incidence of galactorrhea in ovulatory and anovulatory females. Obstet Gynecol 45: 13–14PubMedGoogle Scholar
  54. Kaiser R (1969) Zur Ätiologie und Prophylaxe des Endometriumkarzinoms. Geburtshilfe Frauenheilkd 29: 431PubMedGoogle Scholar
  55. Kleinberg DL, Noel GL, Frantz AG (1977) Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 296: 589–600PubMedCrossRefGoogle Scholar
  56. Kolodny RC, Jacobs LS, Daughaday WH (1972) Mammary stimulation causes prolactin secretion in non-lactating women. Nature 238: 284–286PubMedCrossRefGoogle Scholar
  57. Kramer WM, Rush RF (1973) Mammary duct proliferation in the elderly. Cancer 31: 130–137PubMedCrossRefGoogle Scholar
  58. Kubista E, Müller G, Spona J (1984) Treatment of painful mastopathy. A prospective randomized trial. In: International congress, endocrinology of the breast. Torino, Italy. NY Acad Sci (Abstract 120 )Google Scholar
  59. Kumar S, Mansel RE, Hughes LE, Woodhead JS, Edwards CA, Scanlon MF, Newcombe RG (1984) Prolactine response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53: 1311–1315PubMedCrossRefGoogle Scholar
  60. Lang WR, Renwick S, Johnson L, Wyse E (1972) Benign mammary dysplasia. Med J Aust 2: 147–149PubMedGoogle Scholar
  61. Lauersen NH, Wilson KH (1976) The effect of danazol in the treatment of chronic cystic mastitis. Ob-stet Gynecol 48: 93–98Google Scholar
  62. Leucht W, Rabe D, Boos R, Humbert KD, v. Fournier D, Schmidt W (1984) Stellenwert der hochauflösenden Real-Time-Sonographie beim Mammakarzinom. Geburtshilfe Frauenheilkd 44: 557–562PubMedCrossRefGoogle Scholar
  63. LiVolsi VA, Stadel BV, Kelsey JL, Holford TR, White C (1978) Fibrocystic breast disease in oral-contraceptive users. A histopathological evaluation of epithelial atypia. N Engl J Med 299: 381–385Google Scholar
  64. Mancini AM, Aparicio NJ, Vargas CA, Debeljuk L, Guitelman A (1978) Serum levels of prolactin under basal conditions and after administration of sulpiride in normal and galactorrheic women. Fertil Steril 29: 459–461PubMedGoogle Scholar
  65. Mansel RE, Preece PE, Hughes LE (1980) Treatment of cyclical breast pain with bromocriptine. Scott Med J 25: 65–70Google Scholar
  66. Mansel RE, Wisbey JR, Hughes LE (1982) Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet 1: 928–930PubMedCrossRefGoogle Scholar
  67. Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P (1978) Studies on clinical hormonal and pathological correlations in breast fibroadenomas. J Steroid Biochem 9: 1251–1255PubMedCrossRefGoogle Scholar
  68. Masters JRW, Drife JO, Scarisbrick JJ (1977) Cyclic variation of DNA synthesis in human breast epithelium. JNCI 58: 1263–1265PubMedGoogle Scholar
  69. Mauvais-Jarvis P, Kuttenn F, Ohlgiesser C (1974) Résultats du traitement des mastodynies et des mastopathies par la progestérone percutanée. Nouv Presse Mèd 16: 1027–1028Google Scholar
  70. Minton JP, Abou-Issa H, Reiches N, Roseman JM (1981) Clinical and biochemical studies on methylxanthine-related fibrocystic breast disease. Surgery 90: 299–304PubMedGoogle Scholar
  71. Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK (1982) Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 29: 17–21PubMedCrossRefGoogle Scholar
  72. Mühlenstedt D, Böttcher HD, Osmers F (1983) Endokrinologisch-radiologische Aspekte der Galaktorrhö. Medwelt 34: 302–307Google Scholar
  73. Noel GL, Suh HK, Frantz AG (1974) Prolactin release during nursing and breast stimulation in postpartum and nonpostpartum subjects. J Clin Endocrinol Metab 38: 413–423PubMedCrossRefGoogle Scholar
  74. Nordquist S (1970) The synthesis of DNA and RNA in normal human endometrium in shortterm incubation in vitro and its response to oestradiol and progesterone. J Endocrinol 48: 17–28CrossRefGoogle Scholar
  75. Nyirjesy I (1968) Galactorrhea without amenorrhea. Obstet Gynecol 32: 52–57PubMedGoogle Scholar
  76. Ouimet-Oliva D, van Campenhout J, Hébert G, Ladouceur J (1981) Effect of danazol on the radiographic density of breast parenchyma. J Can Assoc Radiol 32: 159–161PubMedGoogle Scholar
  77. Petrakis NL, Mason L, Lee R, Sugimoto B, Pawson S, Catchpool F (1975) Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration. JNNCI 54: 829–833Google Scholar
  78. Peters F, Pickardt CR, Zimmermann G, Breckwoldt M (1981) PRL, TSH, and thyroid hormones in benign breast diseases. Klin Wochenschr 59: 403–407Google Scholar
  79. Peters F, Pickardt CR, Breckwoldt M (1983) Hormonal status of women with benign cystic breast disease: clinical implications. In: Angeli A, Brad-low HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven, New York, pp 113–122Google Scholar
  80. Preece PE, Richards AR, Owen GM, Hughes LE (1975) Mastalgia and total body water. Br Med J 4: 498–500PubMedCrossRefGoogle Scholar
  81. Preece PE, Baum M, Mansel RE, Webster DJT, Fora RW, Gravelle IH, Hughes LE (1982) Importance of mastalgia in operable breast cancer. Br Med J 284: 1299–1300CrossRefGoogle Scholar
  82. Rannevik G, Döberl A, Gershagen S, Rasmussen Th, Tobiassen T (1983) Elevated serum concentrations of sex hormone binding globulin in fibrocystic breast disease. In: Angeli A, Bradlow HL, Dogliotti L (eds) Endocrinology of cystic breast disease. Raven, New York, pp 127–134Google Scholar
  83. Rasmussen Th, Döberl A, Rannevik G, Tobiassen T (1984) The Hjerring project on fibrocystic breast disease. In: Baum M, George WD, Hughes LE (eds) Benign breast disease. The Royal Society of Medicine, London. 76: 135–139Google Scholar
  84. Reed MJ (1983) Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43: 3940–3942PubMedGoogle Scholar
  85. Ricciardi I, Ianniruberto A (1979) Tamoxifen-Induced Regression of Benign Breast Lesions. Obstet Gynecol 54: 80–84PubMedCrossRefGoogle Scholar
  86. Schulz KD, Del Pozo E, Lose KH, Künzig HJ, Geiger W (1975) Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch Gynäkol 220: 83–87PubMedCrossRefGoogle Scholar
  87. Secreto G, Recchione C, Fariselli G, Di Pietro S (1984) High testosterone and low progesterone circulating levels in premenopausal patients with hyperplasia and cancer of the breast. Cancer Res 44: 841–844PubMedGoogle Scholar
  88. Sitruk-Ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P (1977) Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab 44: 771–774PubMedCrossRefGoogle Scholar
  89. Sundaram GS, London R, Margolis S, Wenk R, Lustgarten J, Nair PP, Goldstein P (1981) Serum hormones and lipoproteins in benign breast disease. Cancer Res 41: 3814–3816PubMedGoogle Scholar
  90. Tabâr L, Dean PB (1982) Mammographic parenchymal patterns. Risk indicator for breast cancer? JA-MA 247: 185–189CrossRefGoogle Scholar
  91. Tarquini B, Benvenuti M, Legnaioli M, Bazzani M, Cagnoni M, Halberg F (1981) Mammary cancer risk: circulating TSH and prolactin fibrocystic breast disease in chronoepidemiologic perspective. Cancer Detec Prey 4: 525–534Google Scholar
  92. Teubner J, Junkermann H, van Kaick G, Pickenhan L, Wesch H, Eggert-Kruse W, v. Fournier D, Kubli F (1984) Diagnostische Wertigkeit der Mammasonographie bei Anwendung eines linearen 5 MHZ-Realtine-Scanners (LS 3000, Fa. Picker). Ergebnisse einer prospektiven Studie. In: Lutz H, Reichel L (Hrsg) Ultraschalldiagnostik 83. Thieme, Stuttgart, S 89–92Google Scholar
  93. Thomas BS, Kirby P, Symes EK, Wang DY (1976) Plasma dehydroepiandrosterone concentration in normal women and in patients with benign and malignant breast disease. Eur J Cancer 12: 405–409PubMedGoogle Scholar
  94. Vetter L, Kraner F, Wyss H (1974) Galactorrhea. Arch Gynecol 216: 81–90Google Scholar
  95. Walsh PV, Morris K, McDicken IW, Whitehouse GN, George WD (1984) Luteal phase function and benign breast disease. In: Baum M, George WD, Hughes LE (eds) Benign breast disease. The Royal Society of Medicine, London, pp 53–62Google Scholar
  96. Wang DY, Hayward JL, Bulbrook RD (1966) Testosterone levels in the plasma of normal women and patients with benign breast disease or with breast cancer. Eur J Cancer 2: 373–376PubMedGoogle Scholar
  97. Watt-Boolsen S, Andersen AN, Blichert-Toft M (1981) Serum prolactin and oestradiol levels in women with cyclical mastalgia. Horm Metab Res 13: 700–702PubMedCrossRefGoogle Scholar
  98. Wolfe JN (1976) Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37: 2486–2492PubMedCrossRefGoogle Scholar
  99. Wynder EL, Hill P, Laakso K, Littner R, Kettunen K (1981) Breast Secretion in Finnish women: a metabolic epidemiologic study. Cancer 47: 1444–1450PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • H. Junkermann

There are no affiliations available

Personalised recommendations